As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
Clyde & Co has been hit with a lawsuit by insurers who say they were wrongly advised to indemnify a builder in a legal dispute.
A top barrister known for work in commercial disputes and class actions has joined the bench of the NSW Supreme Court.
AI tech company Paige can’t patent a tool to provide quality control for analysis of pathology images, with IP Australia finding the invention is merely an “administrative scheme” to automate the role of human pathologists.
Two class actions have been filed alleging racial discrimination by New South Wales and Western Australia over the placement of children in state care.
US animal drug manufacturer Zoetis has lost its challenge a ruling that chucked out three of its patents for a single-dose vaccine to protect pigs from enzootic pneumonia.
CBA has attacked two failed class actions’ “misguided” appeal, arguing that requiring companies to disclose incomplete information to shareholders would distort the market.
The Full Court has heard that a judge’s finding on materiality in two failed shareholder class actions against CBA could have “troubling” repercussions for insider trading cases and must be overturned.
A judge has called out the “combative correspondence” between solicitors at Corrs Chambers and another law firm in a construction defects suit.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.